Our Pricing

Not Losing Weight On Wegovy Vs Mounjaro: A Clinical Comparison

If you're not losing weight on Wegovy vs Mounjaro as expected, understanding the pharmacological differences between these GLP-1 receptor agonists is essential. Semaglutide (Wegovy) and tirzepatide (Mounjaro) demonstrate distinct mechanisms of action, with clinical trials showing variable individual responses that may explain weight loss plateaus. Our UK-registered clinical team at Cured Pharmacy provides expert assessment to help you optimise your treatment pathway.

Why You're Not Losing Weight On Wegovy Vs Mounjaro: Understanding Individual Response

When patients report not losing weight on Wegovy vs Mounjaro, the explanation often lies in individual metabolic variation and receptor sensitivity. Wegovy (semaglutide) acts solely as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) uniquely targets both GLP-1 and GIP receptors, creating a dual incretin effect [1]. This dual mechanism may produce superior weight reduction in certain patient populations, particularly those with insulin resistance or metabolic syndrome.

Clinical trial data from the STEP programme showed that approximately 15-20% of Wegovy patients achieved less than 5% total body weight loss, whilst the SURPASS-2 head-to-head trial demonstrated tirzepatide's superior efficacy across all dose comparisons [2]. However, individual response depends on numerous factors including baseline insulin sensitivity, genetic polymorphisms affecting GLP-1 receptor expression, dietary adherence, and concurrent medication use. If you're experiencing a weight loss plateau on Wegovy, switching to Mounjaro may offer enhanced results through its additional GIP receptor activation, though this requires clinical assessment by a UK prescriber.

Pharmacological Differences: Not Losing Weight On Wegovy Vs Mounjaro Mechanisms

The pharmacological distinction between not losing weight on Wegovy vs Mounjaro centres on receptor selectivity and downstream metabolic effects. Semaglutide demonstrates 94% homology to native human GLP-1 and primarily reduces appetite through hypothalamic pathways, delays gastric emptying, and improves glycaemic control [3]. Tirzepatide's dual agonism adds GIP receptor activation, which enhances insulin secretion, reduces glucagon more effectively, and may improve adipocyte function and energy expenditure.

Patients not responding optimally to Wegovy may benefit from Mounjaro's enhanced insulinotropic effect and greater impact on postprandial glucose excursions. The SURPASS-2 trial directly compared 15mg tirzepatide against 1mg semaglutide, showing mean weight reductions of 12.4kg versus 6.2kg respectively at 40 weeks [2]. This pharmacological advantage stems from GIP's complementary action on pancreatic beta cells and potential effects on central appetite regulation distinct from GLP-1 pathways alone.

Dose Escalation and Therapeutic Ceiling

When evaluating not losing weight on Wegovy vs Mounjaro, dose optimisation plays a critical role. Wegovy's maximum licensed dose is 2.4mg weekly, whilst Mounjaro escalates to 15mg weekly, offering greater dose flexibility for non-responders. Some patients reach a therapeutic ceiling with semaglutide where further dose increases yield diminishing returns, whereas tirzepatide's higher dosing range may overcome this limitation. Our superintendent pharmacist Tarun Kumar regularly assesses patients for appropriate dose titration based on individual tolerance and weight loss trajectory.

Clinical Evidence: Not Losing Weight On Wegovy Vs Mounjaro Trial Data

Robust clinical evidence comparing not losing weight on Wegovy vs Mounjaro outcomes comes from the SURPASS-2 trial, the only head-to-head comparison of these agents. At 40 weeks, tirzepatide 5mg, 10mg, and 15mg produced weight reductions of 7.6kg, 9.3kg, and 11.2kg respectively, compared to 5.7kg with semaglutide 1mg [2]. Importantly, the proportion of patients achieving ≥15% weight loss was significantly higher across all tirzepatide doses (27-40%) versus semaglutide (19%).

The STEP 1 trial demonstrated that Wegovy 2.4mg produced average weight loss of 14.9% at 68 weeks, whilst SURMOUNT-1 showed Mounjaro 15mg achieved 20.9% reduction at 72 weeks [4]. These trials used similar patient populations (BMI ≥30 or ≥27 with comorbidities), making comparisons meaningful. For patients not losing weight on Wegovy vs Mounjaro, these data suggest tirzepatide may offer superior efficacy, though individual response varies and both medications require lifestyle modification for optimal results.

Responder Analysis and Predictive Factors

Post-hoc analyses of patients not losing weight on Wegovy vs Mounjaro reveal predictive factors for treatment response. Higher baseline HbA1c, greater insulin resistance (measured by HOMA-IR), and elevated triglycerides correlate with better relative response to tirzepatide's dual incretin action [1]. Conversely, patients with primarily hypothalamic-driven appetite dysregulation may respond adequately to Wegovy's GLP-1-only mechanism. Genetic studies suggest variations in GLP-1 receptor genes may predict semaglutide response, though routine genetic testing is not yet standard practice in UK weight management services.

Switching Strategy: Not Losing Weight On Wegovy Vs Mounjaro Transition Protocol

For patients not losing weight on Wegovy vs Mounjaro, switching between these medications requires careful clinical planning. The recommended protocol involves discontinuing semaglutide and initiating tirzepatide at the standard 2.5mg starting dose, regardless of prior Wegovy dose, to minimise gastrointestinal adverse effects [5]. Cross-tolerance between GLP-1 receptor agonists means some patients experience reduced side effects when switching, whilst others may encounter renewed nausea during the transition period.

Our UK-registered prescribers assess switching suitability based on several criteria: duration of Wegovy treatment (minimum 12-16 weeks at maintenance dose), documented weight loss plateau (less than 2% body weight change over 8 weeks), medication adherence, and concurrent lifestyle modification efforts. Switching is not appropriate for patients who have not optimised dietary intake or physical activity, as no medication overcomes poor lifestyle adherence. The transition typically shows renewed weight loss within 4-8 weeks if tirzepatide's dual mechanism addresses the underlying cause of Wegovy non-response.

Cost Considerations: Not Losing Weight On Wegovy Vs Mounjaro UK Pricing

When evaluating not losing weight on Wegovy vs Mounjaro, cost-effectiveness becomes relevant for UK patients paying privately. At Cured Pharmacy, Wegovy starts from £124.99 whilst Mounjaro begins at £124.99, with pricing varying by dose strength. New patients receive £20 off their first order using code Weightlossnew, making initial treatment more accessible. These represent the cheapest UK prices for genuine licensed medications, with transparent upfront pricing before consultation.

Cost-per-kilogram weight loss calculations from clinical trials suggest tirzepatide may offer superior value despite higher absolute cost, particularly at higher doses where the efficacy gap widens [4]. However, individual financial circumstances and response patterns determine optimal value. Some patients achieve excellent results with Wegovy at lower cost, whilst others require Mounjaro's enhanced efficacy to reach clinically meaningful weight reduction (≥5% body weight). Our clinical team provides personalised cost-benefit analysis during your assessment.

NHS Availability and Private Prescription Pathways

NHS England currently restricts both Wegovy and Mounjaro to specialist weight management services due to supply constraints and NICE guidance limitations, creating extended waiting lists for eligible patients. Private prescription through UK-registered pharmacies like Cured Pharmacy offers immediate access following clinical assessment by our prescribers. All patients complete a comprehensive medical questionnaire reviewed by GPhC-registered clinicians, ensuring safe prescribing aligned with MHRA licensing and contraindication screening. This pathway suits patients not losing weight on Wegovy vs Mounjaro who require timely treatment optimisation without prolonged NHS waiting periods.

Optimising Outcomes: Not Losing Weight On Wegovy Vs Mounjaro Lifestyle Factors

Addressing not losing weight on Wegovy vs Mounjaro requires examining lifestyle factors that influence medication efficacy. Both semaglutide and tirzepatide amplify the weight loss achieved through caloric restriction, but cannot overcome persistent caloric surplus. Clinical trials mandated 500kcal daily deficits and regular physical activity, yet real-world adherence often falls short [3]. Patients experiencing plateaus should review dietary intake with particular attention to liquid calories, ultra-processed foods, and portion sizes that may have gradually increased during treatment.

Protein intake deserves special consideration when not losing weight on Wegovy vs Mounjaro, as inadequate protein (less than 1.2g per kg ideal body weight) can reduce metabolic rate and lean muscle preservation during weight loss. Resistance training twice weekly helps maintain muscle mass, supporting sustained metabolic rate even as total body weight decreases. Sleep quality, stress management, and certain medications (including some antidepressants, antipsychotics, and corticosteroids) significantly impact weight loss trajectory regardless of GLP-1 or dual incretin therapy. Our clinical team at Cured Pharmacy assesses these factors during consultation, providing holistic guidance beyond medication selection alone.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
3. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5mg solution for injection. MHRA UK. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.